Financial Statements

Coherus BioSciences, Inc. (CHRS)

$2.3

+0.17 (+7.98%)
Income Statement
Balance Sheet
Cash Flow

Income Statement

All numbers are in thousands , Years are calendar years not fiscal years

Retained Earning Schedule

Year 2022 2021 2020 2019 2018
Retained Earnings (Previous Year) -1,050-763-895-985-
Net Income -327-30613290-209
Stock Dividends 3519---775
Dividend Paid -----
Retained Earnings -1,342-1,050-763-895-985

PPE Schedule

Year 2022 2021 2020 2019 2018
Gross PPE 820167-
Annual Depreciation 3-1111237
Capital Expenditure -2-1-7-13-1
Net PPE 9820167

Intangible and Goodwill Schedule

Year 2022 2021 2020 2019 2018
Intangible and Goodwill (Previous Year) -1111
New Purchases -43-20-274-182-127
Intangible and Goodwill 1111-

Coherus BioSciences, Inc. income statement is the only one that provides an overview of company sales and net income
The reasoning behind the adjustment, however, is that free cash flow is meant to measure money being spent right now, not transactions that happened in the past. This makes Coherus BioSciences, Inc. FCF a useful instrument for identifying growing companies with high up-front costs, which may eat into earnings now but have the potential to pay off later.